TSHR; | |
CTDSP1; RECQL; TDP1; BLM; PKM; HSD17B1; AKR1B1; HSD17B2; ALOX15; NOX4; ALDH1A1; USP2; TNKS; TNKS2; AOX1; | |
MGAM; ACHE; | |
CHRNA7; | |
CFTR; | |
GSK3B; DAPK1; SYK; FLT3; ABL1; MAPK1; EGFR; CDK6; CSNK2A1; | |
CA2; CA12; CA7; CA4; | |
AR; | |
ESR2; ESR1; | |
NR1H4; | |
ESRRB; ESRRA; | |
ALOX5; TYR; MAOA; PTGS2; ALDH2; XDH; | |
HIF1A; TP53; NFKB1; AHR; | |
ABCG2; ABCC1; | |
SLCO1B3; SLCO1B1; | |
RAB9A; NPC1; LMNA; MAPT; THPO; TTR; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Nicotinic acetylcholine receptor | CHRNA7 | Neuronal acetylcholine receptor protein alpha-7 subunit | P36544 | CHEMBL2492 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0020037; heme binding | 7.783E-13 | 9.415E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4, PTGS2, TBXAS1 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 9.684E-13 | 1.110E-09 | ABL1, CA2, CA7, CFTR, EGFR, HIF1A, MAPK1, NPC1, NR1H4, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.785E-12 | 2.091E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.780E-11 | 9.014E-09 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1, NR1H4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.157E-10 | 4.940E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.463E-10 | 6.125E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.949E-10 | 3.093E-07 | ABL1, CA2, CA7, CDK6, CFTR, EGFR, HIF1A, MAPK1, NPC1, NR1H4, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.068E-09 | 2.531E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.806E-08 | 1.560E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.806E-08 | 1.560E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.028E-07 | 2.307E-05 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.665E-07 | 3.435E-05 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.862E-07 | 3.720E-05 | CA12, CA2, CA4, CA7 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.546E-07 | 8.048E-05 | CA12, CA2, CA4, CA7, CFTR |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 4.546E-07 | 8.048E-05 | AKR1B1, ALDH1A1, ALDH2, AOX1, XDH |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 5.533E-07 | 9.412E-05 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, HSD17B2, NOX4, PTGS2, RAB9A, TBXAS1 |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 1.617E-06 | 2.348E-04 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.705E-06 | 3.563E-04 | AHR, AR, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 3.453E-06 | 4.381E-04 | BLM, RECQL, TP53 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.049E-06 | 5.038E-04 | ABCC1, CA2, CA4, EGFR, SLCO1B1, SLCO1B3, TSHR |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.114E-06 | 5.090E-04 | ABCC1, ALOX15, ALOX5, SYK |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.343E-06 | 5.254E-04 | AR, BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, NR1H4, TNKS, TP53 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.689E-06 | 5.641E-04 | AHR, CSNK2A1, HIF1A, MAPT |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 4.920E-06 | 5.854E-04 | CA2, CA7, CFTR |
BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 6.242E-06 | 7.154E-04 | ABL1, AHR, AR, BLM, CHRNA7, CSNK2A1, CTDSP1, CYP2D6, DAPK1, ESR1, ESR2, ESRRA, GSK3B, HIF1A, MAPT, NFKB1, NPC1, NR1H4, PTGS2, TNKS, TNKS2, TP53, USP2, XDH |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 6.436E-06 | 7.337E-04 | AR, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 6.748E-06 | 7.653E-04 | AR, CYP19A1, ESR1 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 6.814E-06 | 7.688E-04 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.600E-06 | 8.439E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 8.498E-06 | 9.161E-04 | ALOX15, ALOX5, PTGS2, SYK |
BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.030E-05 | 1.073E-03 | CYP1A1, EGFR, PTGS2, TP53, TYR |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.164E-05 | 1.179E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 1.221E-05 | 1.225E-03 | AOX1, XDH |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.221E-05 | 1.225E-03 | ESR1, ESR2 |
BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 1.542E-05 | 1.513E-03 | ABL1, CDK6, EGFR, GSK3B, HIF1A, MAPK1, MAPT, PTGS2, SYK, TP53, XDH |
BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 1.842E-05 | 1.775E-03 | CA2, EGFR, SYK |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.861E-05 | 1.785E-03 | ABL1, ACHE, CFTR, EGFR, HIF1A, NR1H4, SYK |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.927E-05 | 1.841E-03 | ABCG2, ABL1, ACHE, AHR, AKR1B1, AR, BLM, CA4, CDK6, CSNK2A1, CTDSP1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, ESR1, ESR2, ESRRA, ESRRB, FLT3, GSK3B, HIF1A, LMNA, MAOA, MAPK1, MAPT, NFKB1, NOX4, NPC1, PKM, PTGS2, RAB9A, RECQL, SYK, TDP1, TNKS, TNKS2, TP53, TYR, XDH |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.106E-05 | 1.982E-03 | AR, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
BP | GO:0008152; metabolic process | GO:1901617; organic hydroxy compound biosynthetic process | 2.259E-05 | 2.104E-03 | AKR1B1, ALOX15, CFTR, CYP19A1, CYP3A4, TYR |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.261E-05 | 2.104E-03 | ALOX15, ALOX5, PTGS2 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.739E-05 | 2.465E-03 | MAPK1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.655E-05 | 3.061E-03 | CYP2D6, CYP3A4 |
BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 3.655E-05 | 3.061E-03 | ABL1, HIF1A |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.655E-05 | 3.061E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.655E-05 | 3.061E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.655E-05 | 3.061E-03 | CYP1A1, CYP3A4 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 4.093E-05 | 3.368E-03 | ABCC1, ABCG2, ABL1, BLM, CDK6, CFTR, CSNK2A1, DAPK1, EGFR, FLT3, GSK3B, MAPK1, PKM, RECQL, SYK, TP53 |
BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 4.557E-05 | 3.635E-03 | EGFR, ESRRB, HIF1A |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 5.555E-05 | 4.320E-03 | ABL1, ALOX15, GSK3B, HIF1A, MAPK1, MAPT, NOX4, TNKS, TNKS2, TP53 |
BP | GO:0009987; cellular process | GO:0045595; regulation of cell differentiation | 6.366E-05 | 4.847E-03 | ABL1, AR, CA2, CDK6, CTDSP1, EGFR, ESRRA, ESRRB, GSK3B, HIF1A, MAPK1, MAPT, NFKB1, PTGS2, SYK, THPO, XDH |
BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 6.366E-05 | 4.847E-03 | AR, CYP1B1, ESR1, ESR2, MAPK1, NFKB1, NR1H4, SYK |
MF | GO:0005488; binding | GO:0000977; RNA polymerase II regulatory region sequence-specific DNA binding | 6.613E-05 | 4.982E-03 | AHR, AR, ESR1, ESR2, ESRRA, ESRRB, HIF1A, NFKB1, NR1H4, TP53 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.748E-05 | 5.067E-03 | ABL1, ALOX15, CHRNA7, EGFR, NOX4, THPO |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.026E-05 | 5.258E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 7.294E-05 | 5.347E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.294E-05 | 5.347E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 7.294E-05 | 5.347E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0005497; androgen binding | 7.294E-05 | 5.347E-03 | ALDH1A1, AR |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 7.585E-05 | 5.487E-03 | CYP1A2, EGFR, ESR1, ESRRA, PTGS2 |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 8.358E-05 | 5.944E-03 | ABL1, ACHE, AKR1B1, CA4, EGFR, NOX4, NPC1, TNKS2, TYR, USP2 |
BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 9.108E-05 | 6.338E-03 | AKR1B1, GSK3B, NFKB1, PKM, TP53, TSHR |
CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 9.110E-05 | 6.338E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
MF | GO:0140110; transcription regulator activity | GO:0001228; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding | 9.190E-05 | 6.373E-03 | AR, ESR1, ESRRA, ESRRB, HIF1A, NFKB1, NR1H4, TP53 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 9.620E-05 | 6.608E-03 | ABCG2, ACHE, AOX1, BLM, CHRNA7, FLT3, MAPT, NFKB1, PTGS2, TYR, XDH |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.024E-04 | 6.945E-03 | CYP19A1, CYP1A2, CYP3A4 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.081E-04 | 7.289E-03 | BLM, GSK3B, HIF1A, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.149E-04 | 7.604E-03 | CYP1B1, HIF1A, PTGS2 |
BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 1.174E-04 | 7.721E-03 | AHR, EGFR, GSK3B, TP53, USP2 |
MF | GO:0003824; catalytic activity | GO:0016614; oxidoreductase activity, acting on CH-OH group of donors | 1.174E-04 | 7.721E-03 | AKR1B1, AOX1, HSD17B1, HSD17B2, XDH |
MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.213E-04 | 7.798E-03 | BLM, RECQL |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.213E-04 | 7.798E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.283E-04 | 8.220E-03 | CYP19A1, CYP3A4, ESR1 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.294E-04 | 8.262E-03 | ABCG2, ABL1, ALOX5, CA4, CFTR, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, LMNA, MAOA, MGAM, NPC1, PTGS2, RAB9A, TNKS, TNKS2, TYR |
BP | GO:0050896; response to stimulus | GO:0035774; positive regulation of insulin secretion involved in cellular response to glucose stimulus | 1.428E-04 | 8.987E-03 | CFTR, HIF1A, NR1H4 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.489E-04 | 9.344E-03 | CSNK2A1, EGFR, FLT3, PKM |
MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 1.535E-04 | 9.604E-03 | ABCC1, ABCG2, NPC1, SLCO1B1, SLCO1B3 |
BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.567E-04 | 9.763E-03 | ABL1, GSK3B, MAPT, TP53 |
BP | GO:0051179; localization | GO:0015721; bile acid and bile salt transport | 1.583E-04 | 9.763E-03 | NR1H4, SLCO1B1, SLCO1B3 |
BP | GO:0008152; metabolic process | GO:0042572; retinol metabolic process | 1.583E-04 | 9.763E-03 | ALDH1A1, CYP1B1, TTR |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.117E-14 | 2.701E-11 | ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, TBXAS1, XDH |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.841E-14 | 6.970E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.402E-10 | 2.518E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.128E-10 | 2.518E-08 | MGAM; MAOA; ALOX15; AKR1B1; PTGS2; CYP2C19; CYP3A4; TYR; CYP19A1; CYP2C9; PKM; ALDH2; HSD17B1; ALOX5; TBXAS1; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; AOX1; XDH |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.410E-10 | 2.518E-08 | CYP2C9; CHRNA7; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.480E-09 | 1.724E-07 | AR; GSK3B; CDK6; FLT3; DAPK1; ABL1; MAPK1; PTGS2; HIF1A; TP53; EGFR; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.002E-09 | 4.586E-08 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.493E-09 | 9.884E-08 | CYP2C9; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.198E-09 | 9.884E-08 | CYP2C9; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; CYP2C19; PTGS2 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.321E-09 | 9.884E-08 | ALDH2; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.283E-09 | 9.884E-08 | SLCO1B1; CA2; SLCO1B3; NR1H4; CYP3A4; CFTR; ABCG2 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.527E-08 | 1.086E-06 | CYP2C9; ALOX5; ALOX15; TBXAS1; CYP2C19; PTGS2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.046E-07 | 1.472E-06 | PKM; FLT3; MAPK1; TP53; HIF1A; EGFR |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.700E-08 | 1.327E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.742E-07 | 6.568E-06 | GSK3B; AR; MAPK1; TP53; EGFR; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.755E-07 | 2.294E-06 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 7.118E-07 | 7.662E-06 | ABCC1; CDK6; ABL1; CYP1B1; MAPK1; PTGS2; TP53; EGFR; NFKB1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.361E-08 | 7.980E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.978E-06 | 3.027E-05 | CDK6; MAPK1; TP53; EGFR; NFKB1 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.589E-06 | 4.420E-05 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 6.854E-06 | 5.972E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.914E-06 | 4.496E-05 | CDK6; ABL1; MAPK1; TP53; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.952E-05 | 4.626E-04 | CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.087E-05 | 3.724E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.512E-05 | 3.880E-04 | GSK3B; ABL1; MAPK1; TP53; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.929E-05 | 2.996E-04 | CDK6; MAPK1; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.926E-05 | 2.328E-04 | GSK3B; MAPK1; TP53; EGFR |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.565E-04 | 8.677E-04 | GSK3B; CDK6; SYK; MAPK1; TP53; EGFR; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.985E-05 | 5.670E-04 | GSK3B; MAPK1; TP53; EGFR; NFKB1 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 7.078E-05 | 4.626E-04 | CDK6; MAPK1; TP53; EGFR |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.126E-05 | 9.363E-05 | DAPK1; MAPK1; TP53; EGFR |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.115E-04 | 6.471E-04 | GSK3B; SYK; MAPK1; NFKB1 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.000E-04 | 6.102E-04 | CDK6; MAPK1; TP53; EGFR |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.200E-04 | 1.150E-03 | GSK3B; ABL1; MAPK1; EGFR |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.104E-04 | 1.132E-03 | CDK6; PTGS2; TP53; NFKB1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 6.224E-04 | 2.773E-03 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.364E-04 | 2.773E-03 | MAPK1; TP53; HIF1A; ESR1; EGFR |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.608E-04 | 1.738E-03 | MAPK1; ESR1; EGFR; ESR2 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.195E-04 | 1.968E-03 | MAPK1; HIF1A; EGFR; NFKB1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.842E-04 | 1.406E-03 | SYK; CSNK2A1; PTGS2; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.324E-03 | 5.155E-03 | LMNA; MAPK1; TP53; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.464E-04 | 3.177E-03 | ABCC1; MAPK1; TP53; NFKB1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.756E-03 | 6.427E-03 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.545E-03 | 5.770E-03 | CDK6; MAPK1; TP53; NFKB1 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 8.438E-04 | 3.509E-03 | GSK3B; CDK6; ABL1; TP53 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.715E-03 | 1.488E-02 | MAPK1; CFTR; NFKB1; TSHR |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.466E-03 | 2.102E-02 | ABL1; MAPK1; EGFR; NFKB1 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 4.804E-03 | 1.490E-02 | GSK3B; MAPK1; TYR |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 9.645E-04 | 3.923E-03 | FLT3; MAPK1; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.232E-03 | 4.900E-03 | GSK3B; MAPK1; TP53 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 6.418E-03 | 1.864E-02 | ACHE; CHRNA7; MAPK1 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.939E-03 | 1.506E-02 | MAPK1; HIF1A; EGFR |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 6.259E-03 | 1.848E-02 | MAPK1; PTGS2; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.972E-03 | 7.077E-03 | MAPK1; PTGS2; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 5.358E-03 | 1.608E-02 | GSK3B; MAPK1; NFKB1 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.051E-03 | 7.217E-03 | CSNK2A1; MAPK1; EGFR |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 8.319E-03 | 2.239E-02 | SYK; TBXAS1; MAPK1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 7.594E-03 | 2.106E-02 | ALOX5; MAPK1; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.031E-02 | 2.694E-02 | SYK; MAPK1; NFKB1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.412E-03 | 5.384E-03 | ABL1; MAPK1; NFKB1 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 9.282E-03 | 2.462E-02 | GSK3B; ABL1; MAPK1 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.813E-07 | 3.432E-06 | CA12; CA2; CA4; CA7 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.255E-02 | 2.985E-02 | GSK3B; ESRRB; MAPK1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.255E-02 | 2.985E-02 | GSK3B; CSNK2A1; TP53 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.303E-02 | 3.056E-02 | SYK; MAPK1; EGFR |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.667E-02 | 3.720E-02 | MAPK1; PTGS2; EGFR |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.959E-02 | 4.169E-02 | GSK3B; MAPK1; MAPT |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.179E-02 | 4.443E-02 | GSK3B; MAPK1; NFKB1 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 4.506E-04 | 2.061E-03 | ABCC1; CFTR; ABCG2 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.277E-02 | 4.481E-02 | SYK; MAPK1; NFKB1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.344E-02 | 4.516E-02 | FLT3; TP53; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.516E-02 | 4.796E-02 | CSNK2A1; TP53; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.587E-02 | 4.880E-02 | GSK3B; MAPK1; NFKB1 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.276E-04 | 1.157E-03 | MAOA; AOX1; TYR |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.246E-02 | 4.468E-02 | SYK; MAPK1 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.124E-02 | 4.418E-02 | MAPK1; HIF1A |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.559E-02 | 3.565E-02 | PTGS2; TSHR |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.629E-02 | 4.909E-02 | CA2; CFTR |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.776E-02 | 3.869E-02 | MAPK1; HIF1A |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.832E-02 | 3.944E-02 | MAPK1; PTGS2 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.695E-02 | 4.982E-02 | MAPK1; NFKB1 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.246E-02 | 4.468E-02 | EGFR; NFKB1 |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 2.308E-02 | 4.494E-02 | CDK6; TP53 |
hsa00010 | Glycolysis / Gluconeogenesis_Homo sapiens_hsa00010 | 2.185E-02 | 4.443E-02 | PKM; ALDH2 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.612E-02 | 3.641E-02 | MAPK1; NFKB1 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.720E-02 | 3.793E-02 | ALDH2; AKR1B1 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.506E-02 | 3.489E-02 | GSK3B; TP53 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.208E-02 | 2.985E-02 | MAOA; NFKB1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.162E-02 | 2.912E-02 | PKM; MAPK1 |
hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 1.162E-02 | 2.912E-02 | ALDH2; AOX1 |
hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 1.256E-02 | 2.985E-02 | ALDH2; MAOA |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.071E-02 | 2.759E-02 | CYP3A4; XDH |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.358E-03 | 1.424E-02 | MAPK1; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.659E-03 | 1.488E-02 | MGAM; AKR1B1 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 3.784E-03 | 1.259E-02 | MAPK1; EGFR |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 8.174E-03 | 2.233E-02 | PKM; ALDH2 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 6.660E-03 | 1.904E-02 | ALDH2; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.752E-03 | 9.502E-03 | CA2; CA4 |
hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 2.995E-03 | 1.015E-02 | ALDH2; MAOA |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.132E-04 | 6.471E-04 | CYP1A2; XDH |
hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 2.023E-02 | 4.255E-02 | AOX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; AKR1B1; MGAM |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; EGFR; PTGS2 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; ALDH2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Melanoma | C43 | TYR; EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM |
NA: NA | Postmenopausal disorder | NA | ESR1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK; TBXAS1 |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | CHRNA7 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; PTGS2 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; TBXAS1; CHRNA7; PTGS2; ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; ABCC1; ESRRA |
NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; MAOA |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; EGFR; EGFR |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | CHRNA7 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; NFKB1; PTGS2; MGAM |
NA: NA | HIV infections | NA | AHR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; CHRNA7; MAPT |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
NA: NA | GIST | NA | FLT3 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRNA7 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; CHRNA7; MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ABL1; ESR1 |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
NA: NA | Upper abdominal bloating | NA | ACHE |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CHRNA7; MAPT |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ABL1; EGFR; ESR1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
C00-D49: Neoplasms | AML | NA | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; CHRNA7; CHRNA7; MAOA; PTGS2; MAPT |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; MGAM |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | CHRNA7 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; SYK; HIF1A; TP53; MAPK1; FLT3; FLT3; ABL1; NFKB1; ACHE; EGFR; ESR1; ESR1; PTGS2; CSNK2A1 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; EGFR; EGFR; EGFR; ESR1; ESR1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; HIF1A; TP53; MAPK1; FLT3; ABL1; EGFR; PKM |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
NA: NA | Male hypogonadism | NA | AR |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; SYK; AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2; ESRRA |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR; PTGS2 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; ESRRA |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PTGS2; ABCC1; ABCC1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRNA7; CHRNA7; CHRNA7; ESRRA |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; CHRNA7 |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |